Products
Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-1035
Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-1035-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-1035-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-1035-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-1035-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 |
| INN Name | Tucotuzumab Celmoleukin |
| Target | EPCAM |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - nd |
| VD LC | IgG1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Merck Serono International S.A. (Geneva Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
